Welcome to our dedicated page for Enliven Therapeutics news (Ticker: ELVN), a resource for investors and traders seeking the latest updates and insights on Enliven Therapeutics stock.
Enliven Therapeutics Inc (ELVN) is a clinical-stage biopharmaceutical company pioneering targeted therapies for cancer treatment through precision oncology. This page serves as the definitive source for verified corporate announcements, research milestones, and financial disclosures.
Investors and industry observers will find timely updates on clinical trial progress, regulatory developments, and strategic partnerships. Our curated collection includes press releases covering drug candidate advancements, peer-reviewed research highlights, and material business events.
Key focus areas include updates on ELVN's small molecule kinase inhibitor pipeline, CNS-penetrant therapies, and collaborations advancing oncology treatment paradigms. All content undergoes strict verification to ensure compliance with financial disclosure standards.
Bookmark this page for direct access to primary source materials from Enliven Therapeutics, formatted for clarity across devices. Regularly refreshed content supports informed analysis of the company's position in the competitive oncology therapeutics landscape.
Enliven Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the Jefferies London Healthcare Conference on November 19, 2024, at 9:30 a.m. GMT. The company's management will engage in a fireside chat, which will be webcast live. Interested parties can access the webcast via the investor relations section of Enliven's website. The webcast will remain available for 90 days post-event.
Enliven Therapeutics (Nasdaq: ELVN) has announced details for the presentation of updated ELVN-001 Phase 1a data at the ESH-iCMLf 26th Annual John Goldman Conference on CML. The event will take place from September 27-29 in Prague, Czech Republic. ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia (CML) patients.
The oral presentation, titled "Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML," will be delivered by Dr. Fabian Lang from Goethe University Hospital on September 28, 2024, at 3:35 p.m. CEST. The presentation will be part of Scientific Session 5: New drugs and combinations. Enliven will make the presentation available on their website after the conference.
Enliven Therapeutics (Nasdaq: ELVN) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Dosing of first patients in Phase 1b arm for ELVN-001 in CML and Phase 1a trial for ELVN-002 in HER2+ MBC and CRC.
2. Strong financial position with $312.4 million in cash, providing runway into late 2026.
3. R&D expenses increased to $18.8 million in Q2 2024 from $15.2 million in Q2 2023.
4. Net loss widened to $20.0 million in Q2 2024 from $16.7 million in Q2 2023.
5. Upcoming presentation of updated ELVN-001 Phase 1a data at ESH-iCMLf Conference in September 2024.
Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage precision oncology company, has announced its participation in two investor conferences in June 2024. The company will present at the Jefferies Global Healthcare Conference on June 5 at 8:30 a.m. ET and the Goldman Sachs Annual Global Healthcare Conference on June 10 at 3:20 p.m. ET. Both events will feature fireside chats with Enliven's management. The sessions will be webcast live and available on the company's investor relations website, with archives accessible for 30 days post-event.
Enliven Therapeutics announced positive results from its Phase 1 trial of ELVN-001 for chronic myeloid leukemia, showing a 44% major molecular response (MMR) rate by 12 weeks. The company has $321 million in cash, extending its runway to late 2026. A $90 million PIPE financing and board appointment of Lori Kunkel were highlighted. Enliven also advanced its ELVN-002 trial for HER2+ cancers, with the first site activated and patient dosing expected in Q2 2024. Financial results showed increased R&D and G&A expenses, leading to a net loss of $22.7 million for Q1 2024, compared to $14.7 million in Q1 2023.
FAQ
What is the current stock price of Enliven Therapeutics (ELVN)?
What is the market cap of Enliven Therapeutics (ELVN)?
